Prurigo Nodularis

PN is increasingly recognized as a common and severe inflammatory skin disease disproportionately affecting patients with darker skin tones.

A meaningful difference in WI-NRS scores was observed as early as day 3 of treatment with ruxolitinib cream.

Explore innovative biologic treatments for prurigo nodularis, enhancing patient quality of life and breaking the itch-scratch cycle effectively.

Nearly all injection site reactions among patients in the ARCADIA 1/2 and OLYMPIA 1/2 clinical trials were mild and transient in nature.

Colleagues, mentors, and patients gathered to discuss Kwatra’s immense achievements throughout his career and the milestones that led to his endowed position. 

Tofacitinib showed promise for easing itch and skin symptoms in prurigo nodularis, though effects may lessen over time.

Targeting type 2 cytokines with monoclonal antibodies has revolutionized treatment for inflammatory skin diseases, reducing symptoms and improving quality of life.

Brian S. Kim, MD, FAAD, shares itch research updates at the AAD Annual Meeting.

TJ Chao, MPAS, PA-C, discusses how to approach conversations with patients about starting systemic therapy for prurigo nodularis, emphasizing the importance of setting realistic treatment expectations, promoting long-term adherence, and providing tips for managing biologic agents administered on a bimonthly or monthly basis.

85% of Chinese PN patients saw a PP-NRS improvement of ≥ 4 points after 12 weeks of treatment.

A panelist discusses how the advent of targeted systemic therapies such as dupilumab and nemolizumab has transformed the treatment landscape for prurigo nodularis, offering more effective options for breaking the itch-scratch cycle while maintaining favorable safety profiles compared with traditional systemic treatments.

A panelist discusses how this patient's history of chronic kidney disease, diabetes, and psychological stress are significant contributing factors to his prurigo nodularis, necessitating a comprehensive treatment approach that addresses both the underlying conditions and the itch-scratch cycle.

TJ Chao, MPAS, PA-C, discusses how systemic treatments for prurigo nodularis are considered for patients with moderate to severe disease, highlighting key patient-specific factors such as comorbidities and disease severity when initiating treatment.

A panelist discusses how diagnostic differentiation of prurigo nodularis requires careful examination of the characteristic firm, hyperkeratotic nodules and consideration of the patient's history of chronic pruritus and scratching behavior, while noting that comorbid atopic dermatitis may influence treatment selection toward dual-targeting therapies.

As 2024 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in prurigo nodularis this year.